Purpose: The objective of this study was to evaluate the implementation of a Multidisciplinary Tumor Board (MDTB) strategy in the treatment of patients with uveal melanoma. Methods: A retrospective analysis was conducted on the implementation of MDTB meetings over a 24-month period. During this time, 72 intraocular tumors were discussed, including 59 confirmed cases of uveal melanoma. The MDTB involved a core group of specialists (e.g., ophthalmologists, oncologists, and radiologists), with other experts included when clinically appropriate. To assess patient satisfaction with the MDTB approach, a structured questionnaire was administered, including items on clarity of communication, perceived quality of care, and overall satisfaction, which were ranked on a 5-point scale. Results: A total of 319 patients with ocular, periocular, or orbital tumors were discussed during the study period, of which, 72 had intraocular tumors. A total of 13 (18%) were diagnosed to have choroidal metastases, whereas 59 (82%) had uveal melanomas. The average time between patient care and MDTB discussion was 15.9 days (IQR: 7.5–16.5). The mean time between the case discussion and the implementation of recommendations (diagnostic, therapeutic, or referral decisions) was 14.8 days (IQR: 6.0–23.75). Overall, 4 (7%) patients were classified as Stage I, 16 (27%) as Stage IIa, 18 (31%) as Stage IIb, 7 (12%) as Stage IIIa, 2 (3%) as Stage IIIb, and 12 (20%) as Stage IV. Regarding the satisfaction questionnaire, all patients (100%) agreed to have the clinical case discussed at the TB even though this could result in a delay in diagnostic/therapeutic implementation. However, only 60% of patients perceived they had been directly involved in the decision-making process. Conclusions: In selected cases of uveal melanoma and other types of cancer, MDTBs should be recognized as a gold standard in cancer care, allowing for comprehensive decision-making that draws on a wide range of highly specialized expertise.

Savino, G., Pagliara, M. M., Sammarco, M. G., Caputo, C. G., Blasi, M. A., Mattei, R., Marcelli, S., Tagliaferri, L., Fionda, B., Schinzari, G., Rossi, E., Zagaria, L., Tartaglione, T., Ausili Cefaro, L., Todaro, M., Moro, A., Giannuzzi, F., The Role of Multidisciplinary Ocular and Periocular Cancers Meetings in Uveal Melanoma Management: A 2-Year Analysis, <<CANCERS>>, 2025; 17 (14): N/A-N/A. [doi:10.3390/cancers17142274] [https://hdl.handle.net/10807/319936]

The Role of Multidisciplinary Ocular and Periocular Cancers Meetings in Uveal Melanoma Management: A 2-Year Analysis

Savino, Gustavo;Pagliara, Monica Maria;Sammarco, Maria Grazia;Caputo, Carmela Grazia;Blasi, Maria Antonietta;Mattei, Roberta;Tagliaferri, Luca;Fionda, Bruno;Schinzari, Giovanni;Rossi, Ernesto;Zagaria, Luca;Tartaglione, Tommaso;Ausili Cefaro, Luca;Todaro, Mattia;Moro, Alessandro;Giannuzzi, Federico
2025

Abstract

Purpose: The objective of this study was to evaluate the implementation of a Multidisciplinary Tumor Board (MDTB) strategy in the treatment of patients with uveal melanoma. Methods: A retrospective analysis was conducted on the implementation of MDTB meetings over a 24-month period. During this time, 72 intraocular tumors were discussed, including 59 confirmed cases of uveal melanoma. The MDTB involved a core group of specialists (e.g., ophthalmologists, oncologists, and radiologists), with other experts included when clinically appropriate. To assess patient satisfaction with the MDTB approach, a structured questionnaire was administered, including items on clarity of communication, perceived quality of care, and overall satisfaction, which were ranked on a 5-point scale. Results: A total of 319 patients with ocular, periocular, or orbital tumors were discussed during the study period, of which, 72 had intraocular tumors. A total of 13 (18%) were diagnosed to have choroidal metastases, whereas 59 (82%) had uveal melanomas. The average time between patient care and MDTB discussion was 15.9 days (IQR: 7.5–16.5). The mean time between the case discussion and the implementation of recommendations (diagnostic, therapeutic, or referral decisions) was 14.8 days (IQR: 6.0–23.75). Overall, 4 (7%) patients were classified as Stage I, 16 (27%) as Stage IIa, 18 (31%) as Stage IIb, 7 (12%) as Stage IIIa, 2 (3%) as Stage IIIb, and 12 (20%) as Stage IV. Regarding the satisfaction questionnaire, all patients (100%) agreed to have the clinical case discussed at the TB even though this could result in a delay in diagnostic/therapeutic implementation. However, only 60% of patients perceived they had been directly involved in the decision-making process. Conclusions: In selected cases of uveal melanoma and other types of cancer, MDTBs should be recognized as a gold standard in cancer care, allowing for comprehensive decision-making that draws on a wide range of highly specialized expertise.
2025
Inglese
Savino, G., Pagliara, M. M., Sammarco, M. G., Caputo, C. G., Blasi, M. A., Mattei, R., Marcelli, S., Tagliaferri, L., Fionda, B., Schinzari, G., Rossi, E., Zagaria, L., Tartaglione, T., Ausili Cefaro, L., Todaro, M., Moro, A., Giannuzzi, F., The Role of Multidisciplinary Ocular and Periocular Cancers Meetings in Uveal Melanoma Management: A 2-Year Analysis, <<CANCERS>>, 2025; 17 (14): N/A-N/A. [doi:10.3390/cancers17142274] [https://hdl.handle.net/10807/319936]
File in questo prodotto:
File Dimensione Formato  
The Role of Multidisciplinary Ocular and Periocular Cancers Meetings in Uveal Melanoma Management.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 463.31 kB
Formato Adobe PDF
463.31 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/319936
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact